This week's Fierce Biotech is brought to you by Lonza.

Whitepaper: Antibody Drug Conjugates in Oncology: How Technology Advances Can Streamline Development and Manufacturing

The antibody-drug conjugate (ADC) market is surging, projected to surpass $30 billion by 2030. These transformative therapeutics are revolutionizing cancer care with enhanced safety, efficacy, and improved patient survival rates. To meet the growing demand, advancements in bioconjugation and payload-linker manufacturing are essential. That’s where Lonza leads the way, offering end-to-end solutions that streamline ADC development and production throughout the product lifecycle. What you’ll learn in this whitepaper:

• The exponential growth of ADCs in oncology
• How bioconjugation innovations are shaping the future
• Integrated capabilities for ADC manufacturing

Stay ahead in this fast-growing market with insights that empower your team to innovate and excel.👉 Download your free whitepaper now and explore how technology is driving faster, safer ADC breakthroughs.